Encephalomyelitis - 25 Studies Found
Completed |
: Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone :
: Procedure: Plasma exchange |
Active, not recruiting |
: Biobank For MS And Other Demyelinating Diseases :
|
Enrolling by invitation |
: Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine : Venezuelan Equine Encephalomyelitis : 2007-12-19 : Biological: VEE TC-83 Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper oute |
Recruiting |
: Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) :
: 2016-12-19 :
|
Completed |
: The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome :
: 2005-09-16 : Drug: Ampligen |
Terminated |
: Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome :
: 2012-11-08 : Drug: Etanercept Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months. |
Recruiting |
: Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients :
: |
Recruiting |
: Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health : Chronic Fatigue Syndrome : 2016-01-29 |
Terminated |
: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome :
: 2010-07-02 : Drug: Rituximab Two infusions of Rituximab 500 mg/m2 (max |
Completed |
: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome :
: 2010-07-02 : Drug: Rituximab Two infusions of Rituximab 500 mg/m2 (max |